Seres Therapeutics (MCRB) Stock Spikes in Initial Public Offering

NEW YORK (TheStreet) -- Seres Therapeutics  (MCRB) shares are gaining, up 91.72% to $34.51, in the biotech company's first day of trading on the Nasdaq.

The Cambridge, MA-based company priced its upsized public offering of 7.43 million shares at $18 per share.

The company had previously said that it would offer 6.25 million shares between the $15 and $17 per share range.

Seres Therapeutics' lead development candidate, SER-109, is an oral therapeutic for the prevention of Clostridium difficile infection which affects between 85,000 and 110,000 people in the U.S.

The drug candidatite is currently in Phase II trials.

The company also has five other drug candidates in its development pipeline at various trial stages

MCRB Price Chart MCRB Price data by YCharts

If you liked this article you might like

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics

Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Seres Therapeutics (MCRB) Stock Surges, FBR Capital Remains Bullish

Seres Therapeutics (MCRB) Stock Surges, FBR Capital Remains Bullish